Literature DB >> 2327771

Pharmacokinetics and inflammatory fluid penetration of cefpodoxime proxetil in volunteers.

P O'Neill1, K Nye, G Douce, J Andrews, R Wise.   

Abstract

The pharmacokinetics of cefpodoxime were determined after a single oral dose of 261 mg of cefpodoxime proxetil, equivalent to 200 mg of cefpodoxime, was given to each of six healthy male volunteers. Concentrations in serum, urine, and cantharidin-induced inflammatory fluid were measured by a microbiological assay. The mean peak level in plasma was 2.1 micrograms/ml, attained at a mean time of 2.9 h. The mean half-life of elimination from serum was 2.2 h. The inflammatory exudate was penetrated moderately rapidly, the mean peak level being 1.7 micrograms/ml at 3.5 h. The mean percent penetration of the inflammatory exudate was 103.7. The mean 24-h urine recovery of cefpodoxime was 32.2%. This study suggests that cefpodoxime proxetil taken once or twice daily will be sufficient to treat urinary or systemic infections caused by susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327771      PMCID: PMC171563          DOI: 10.1128/AAC.34.2.232

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

3.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

4.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

5.  A comparison of the pharmacokinetics and tissue penetration of ceftriaxone, moxalactam and cefotaxime.

Authors:  R Wise; J M Andrews
Journal:  Eur J Clin Microbiol       Date:  1983-10       Impact factor: 3.267

6.  Clindamycin elimination in patients with liver disease.

Authors:  R H Eng; S Gorski; A Person; C Mangura; H Chmel
Journal:  J Antimicrob Chemother       Date:  1981-10       Impact factor: 5.790

7.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

8.  Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.

Authors:  J W Stone; G Linong; J M Andrews; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

9.  Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.

Authors:  C C Knapp; J Sierra-Madero; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

10.  Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin.

Authors:  J Kavi; J M Andrews; J P Ashby; G Hillman; R Wise
Journal:  J Antimicrob Chemother       Date:  1988-12       Impact factor: 5.790

View more
  14 in total

1.  Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.

Authors:  J V St Peter; M T Borin; G S Hughes; J S Kelloway; B E Shapiro; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 2.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Cefpodoxime proxetil in the treatment of skin and soft tissue infections.

Authors:  K J Tack; N E Wilks; G Semerdjian; C H Frazier; K Shirin; A Puopolo; S G Crossland; B S Goffe; L Millikan
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

6.  Pharmacokinetics of cefetamet in plasma and skin blister fluid.

Authors:  W Zimmerli; S Sansano; B Wittke
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 7.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 8.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

9.  Oral cephalosporins for use in a parenteral-to-oral switch programme.

Authors:  D M Rimmer
Journal:  Infection       Date:  1995       Impact factor: 3.553

10.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.